{"name":"Dhp Korea Co., Ltd.","slug":"dhp-korea-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AT03","genericName":"AT03","slug":"at03","indication":"Other","status":"phase_2"},{"name":"AT04","genericName":"AT04","slug":"at04","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AT01","genericName":"AT01","slug":"at01","indication":"Type 2 diabetes","status":"phase_2"},{"name":"AT02","genericName":"AT02","slug":"at02","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AT03","genericName":"AT03","slug":"at03","phase":"phase_2","mechanism":"AT03 is a small molecule that targets the [unknown] mechanism.","indications":[],"catalyst":""},{"name":"AT04","genericName":"AT04","slug":"at04","phase":"phase_2","mechanism":"AT04 is an investigational drug with unknown mechanism of action.","indications":[],"catalyst":""},{"name":"AT01","genericName":"AT01","slug":"at01","phase":"phase_2","mechanism":"AT01 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AT02","genericName":"AT02","slug":"at02","phase":"phase_2","mechanism":"AT02 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}